Valuation: Rapport Therapeutics, Inc.

Market Cap 1.94B 1.69B 1.59B 1.45B 2.72B 186B 2.73B 19.09B 7.35B 94.72B 7.29B 7.13B 305B P/E 2026 *
-9.79x
P/E 2027 * -8.09x
Enterprise Value 1.61B 1.41B 1.32B 1.21B 2.26B 154B 2.26B 15.85B 6.11B 78.66B 6.05B 5.92B 254B EV / Sales 2026 *
80.6x
EV / Sales 2027 * -
Free-Float
96.1%
Yield 2026 *
-
Yield 2027 * -
1 day-1.95%
1 week-9.08%
Current month-18.51%
1 month-17.12%
3 months+6.21%
6 months+46.45%
Current year+30.72%
1 week 39.11
Extreme 39.11
43.98
1 month 39.11
Extreme 39.11
52.93
Current year 25.21
Extreme 25.21
52.93
1 year 23.75
Extreme 23.75
52.93
3 years 6.43
Extreme 6.43
52.93
5 years 6.43
Extreme 6.43
52.93
10 years 6.43
Extreme 6.43
52.93
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 2022-12-31
Chief Executive Officer 48 2023-01-31
Director of Finance/CFO 58 2023-10-31
Director TitleAgeSince
Director/Board Member 61 2023-08-22
Director/Board Member 48 2023-02-28
Director/Board Member 54 2022-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 Sell

Chief Executive Officer

-8,210 0.0171%
8/25/26 Sell

Executive/Senior Manager

-37,000 0.0774%
8/25/26 Sell

Chief Executive Officer

-18,921 0.0396%
Change 5-day change 1-year change 3-year change Capi.($)
-1.95%-9.08%+50.46% - 1.94B
+0.59%+3.31%+1.03%+24.53% 46.28B
+1.30%+3.10%+44.15%+31.38% 43.85B
+0.95%-5.40%+342.72%+548.37% 40.93B
+4.23%+5.53%+9.35%+89.62% 39.89B
+1.11%+1.80%+11.52%+43.15% 29.5B
+1.94%+6.24%+25.19%+145.07% 17.09B
+0.37%-9.84% - - 15.55B
+2.12%+10.41%+24.78%+39.05% 15.22B
+0.24%+32.23%-11.57% - 14.05B
Average +1.08%+2.85%+55.29%+131.60% 26.43B
Weighted average by Cap. +1.51%+2.01%+70.22%+141.24%

Financials

2026 *2027 *
Net sales 20M 17.45M 16.42M 14.96M 28.06M 1.92B 28.09M 197M 75.78M 976M 75.12M 73.45M 3.15B -
Net income -194M -169M -159M -145M -272M -18.6B -273M -1.91B -736M -9.47B -729M -713M -30.55B -252M -220M -207M -189M -354M -24.18B -355M -2.48B -956M -12.32B -948M -927M -39.72B
Net Debt -329M -287M -270M -246M -462M -31.53B -462M -3.24B -1.25B -16.06B -1.24B -1.21B -51.79B -477M -416M -391M -357M -669M -45.67B -670M -4.69B -1.81B -23.27B -1.79B -1.75B -75.02B
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
26-09-21 US$39.66 -1.95% 616,211
26-09-18 US$40.45 -3.58% 998,058
26-09-17 US$41.95 +1.35% 397,300
26-09-16 US$41.39 -3.02% 387,025
26-09-15 US$42.68 -3.00% 189,312
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
40.45USD
Average target price
62.88USD
Spread / Average Target
+55.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RAPP Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!